National Healthcare Budget Impact Analysis of the Treatment for Osteoporosis and Fractures in Korea
1
조회
0
다운로드
16
인용
0
참고문헌
키워드
초록
Background: This study was to determine the impact on the national healthcare expen-diture for the treatment of osteoporosis and fractures if the coverage period for osteo-porosis medication was extended from maximum a year to continuous period as re-quired. Methods: Preserving the current reimbursement guidelines, maximum one year’s coverage for osteoporosis medication was set as scenario A. Continuous coverage for patients who require medication was set as scenario B. As costs of medical service utili-zation are paid by the Korean National Health Insurance Program, all items were investi-gated and analyzed from the payer’s perspective. The combined treatment costs for os-teoporosis and osteoporotic fractures were assessed for each scenario. Results: Over five years the cost of osteoporosis medication in scenario A will increase from 184.3 billion KRW to 204.6 billion KRW. The cost of osteoporotic fracture treatment will increase from 1,037.3 billion KRW to 1,822.7 billion KRW. In scenario B, the cost of osteoporosis medi-cation will increase from 209.5 billion KRW to 388.1 KRW. The cost of osteoporotic frac-ture treatment will increase from 600.0 billion KRW to 1,054.3 billion KRW. The result showed savings of 2.50 trillion KRW cumulatively for five years when reimbursement cov-erage for osteoporosis treatments is extended from one year to as long as it’s clinically required. Conclusions: This study demonstrates that effective osteoporosis manage-ment through appropriate insurance coverage for osteoporosis medication should be considered not only for the patient’s viewpoint, but in terms of national insurance bud-get as well.
Abstract
Background: This study was to determine the impact on the national healthcare expen-diture for the treatment of osteoporosis and fractures if the coverage period for osteo-porosis medication was extended from maximum a year to continuous period as re-quired. Methods: Preserving the current reimbursement guidelines, maximum one year’s coverage for osteoporosis medication was set as scenario A. Continuous coverage for patients who require medication was set as scenario B. As costs of medical service utili-zation are paid by the Korean National Health Insurance Program, all items were investi-gated and analyzed from the payer’s perspective. The combined treatment costs for os-teoporosis and osteoporotic fractures were assessed for each scenario. Results: Over five years the cost of osteoporosis medication in scenario A will increase from 184.3 billion KRW to 204.6 billion KRW. The cost of osteoporotic fracture treatment will increase from 1,037.3 billion KRW to 1,822.7 billion KRW. In scenario B, the cost of osteoporosis medi-cation will increase from 209.5 billion KRW to 388.1 KRW. The cost of osteoporotic frac-ture treatment will increase from 600.0 billion KRW to 1,054.3 billion KRW. The result showed savings of 2.50 trillion KRW cumulatively for five years when reimbursement cov-erage for osteoporosis treatments is extended from one year to as long as it’s clinically required. Conclusions: This study demonstrates that effective osteoporosis manage-ment through appropriate insurance coverage for osteoporosis medication should be considered not only for the patient’s viewpoint, but in terms of national insurance bud-get as well.
참고문헌 (24)
- Park C, "The incidence and residual lifetime risk of osteoporosis-related fractures in Korea", J Bone Miner Metab, 29, pp.744~751 (2011)
- Kanis JA, "Epidemiology of osteoporosis", Bone, 13(Suppl 1), pp.S7~S15 (1992)
- Lippuner K, "Epidemiology and direct medical costs of osteoporotic fractures in men and women in Switzerland", Osteoporos Int, 16(Suppl 2), pp.S8~S17 (2005)
- Mullen JO, "Hip fracture mortality. A prospective, multifactorial study to predict and minimize death risk", Clin Orthop Relat Res, 280, pp.214~222 (1992)
- Randell AG, "Deterioration in quality of life following hip fracture: a prospective study", Osteoporos Int, 11, pp.460~466 (2000)
- "National health insurance statistical yearbook" (2012)[URL]
- "Details (medicines) on application standards of medical care benefit and methods" (2010)[URL]
- "National health insurance statistical yearbook" (2010)[URL]
- Langdahl BL, "Medical treatment of osteoporotic vertebral fractures", Ther Adv Musculoskelet Dis, 3, pp.17~29 (2011)
- Black DM, "Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group", J Clin Endocrinol Metab, 85, pp.4118~4124 (2000)
- Pueyo MJ, "Cost-utility and budget impact analysis of primary prevention with alendronate of osteoporotic hip fractures in Catalonia", Reumatol Clin, 8, pp.128~134 (2012)
- Muller D, "Cost-effectiveness of different strategies for selecting and treating individuals at increased risk of osteoporosis or osteopenia: a systematic review", Value Health, 15, pp.284~298 (2012)
- Hiligsmann M, "The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland", Value Health, 15, pp.604~612 (2012)
- Borgstrom F, "Health economics of osteoporosis", Best Pract Res Clin Endocrinol Metab, 22, pp.885~900 (2008)
- Zethraeus N, "Cost-effectiveness of the treatment and prevention of osteoporosis--a review of the literature and a reference model", Osteoporos Int, 18, pp.9~23 (2007)
- Johnell O, "Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures", Pharmacoeconomics, 21, pp.305~314 (2003)
- 김상림, "Orthopedic Surgeon’s Awareness Can Improve Osteoporosis Treatment Following Hip Fracture: A Prospective Cohort Study", Journal of Korean Medical Science, 26(11), pp.1501~1507 (2011), 대한의학회
- Colon-Emeric C, "Expert physician recommendations and current practice patterns for evaluating and treating men with osteoporotic hip fracture", J Am Geriatr Soc, 48, pp.1261~1263 (2000)
- Watts NB, "American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis: executive summary of recommendations", Endocr Pract, 16, pp.1016~1019 (2010)
- Qaseem A, "Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians", Ann Intern Med, 149, pp.404~415 (2008)
- Kanis JA, "European guidance for the diagnosis and management of osteoporosis in postmenopausal women", Osteoporos Int, 19, pp.399~428 (2008)
- "Drug reimbursement criteria" (2012)[URL]